top of page
Executive Spotlights

Avenzo Therapeutics announces $150M Oversubscribed Financing to Advance Emerging Oncology Pipeline

San Diego, CA, March 26, 2024 (Business Wire) -- Avenzo Therapeutics concludes an oversubscribed $150 million Series A-1 financing round, bringing total capital raised to $347 million since its founding in August 2022. Led by prominent investors including NEA, Deep Track Capital, and Sofinnova Investments, this funding underscores Avenzo's commitment to advancing next-generation oncology therapeutics. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, will join Avenzo's Board of Directors, enhancing the company's strategic leadership.

Read full article here.

Recent Posts

See All


Life Science Headlines
bottom of page